Abstract
e18143 Background: A study reported in the literature including p with advanced NSCLC showed a strong patient (p) preference for PO treatment while maintaining the efficacy and a good safety profile. As results, two Spanish institutions decided to prescribe the oral form of vinorelbine when administered together with CBDCA in patients unfit to receive cisplatin. Methods: Between May 2008 and June 2009, 17 chemo-naïve p with histologically confirmed stage IIIB/IV NSCLC and unfit to receive cisplatin were treated in 2 Spanish institutions. Treatment consisted of CBDCA AUC5 day 1 plus NVBO 80 mg/m2 days 1 and 8, with a prior test of myelosensitivity at 60 mg/m2 for the first cycle (cy), every 21 days, for a maximum of 6 cy unless progression of the disease was observed earlier. Results: Patient's characteristics were: Median age, 69 years (range 55-82); males, 94%; smokers, 75%; PS 0-1, 94%; adenocarcinoma, 25%/squamous, 69%; stage IIIB, 17.6%/IV, 82.4%. Median number of cy 4 (range 1-6). We analyzed 70 cy. Cycle 2 dose escalation to 80 mg/m2 was performed in 76.5% of p. Hematological toxicities (%p): grade (g) 3/4 neutropenia, 35.3%; g3 anemia, 11.8%. Nonhematological toxicities (%p): respiratory g4, 5.9%; fever g4, 5.9% pain g4, 5.9%; nausea and vomiting g3, 5.9%. 16 p were evaluable for response. 5 PR (31%) and 7 SD (44%) were reported. With a median follow-up of 5.1 months (m), median survival for the whole population was 9.6 m, progression free survival 8 m. Conclusions: The findings of this retrospective analysis when compared to the reported data in the literature in this population suggest that the combination of carboplatin either plus oral or intravenous vinorelbine have a similar efficacy. The use of oral vinorelbine avoids venous toxicity and adds comfort to the day 8 administration. No significant financial relationships to disclose.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call